8-K: TOMI Reports Q2 2025 Loss Amid Sales Decline

TOMI Environmental Solutions, Inc. reported a significant decline in Q2 2025 net sales and a net loss, primarily due to customer deferrals of capital expenditure projects.

Summary

• Net sales for Q2 2025 were $1,031,000, a significant decrease from $3,013,000 in Q2 2024.
• Net sales for the first half of 2025 were $2,608,000, down from $4,127,000 in the first half of 2024.
• The company reported a net loss of $(1,238,000) or $(0.06) per basic and diluted share for Q2 2025, compared to a net income of $30,000 or $0.00 per share in Q2 2024.
• Net loss for the first half of 2025 was $(1,493,000) or $(0.07) per basic and diluted share, compared to $(1,280,000) or $(0.06) per share in the first half of 2024.
• Service and training revenue increased by 33% year-over-year in Q2 2025 and 46% in the first half of 2025.
• Gross profit margin remained healthy at 66% in Q2 2025, up from 62% in Q2 2024.
• Sales order backlog as of June 30, 2025, totaled approximately $1.4 million.
• As of August 7, 2025, the combined total of recognized revenue, deferred revenue, and sales order backlog was approximately $4.6 million.
• Open opportunities for Custom Engineered System (CES), Hybrid Solutions, and SteraMist (SIS) total approximately $15 million, with $7 million designated as high priority.
• Working capital as of June 30, 2025, was $2.8 million, and cash used in operations improved by over $1 million compared to the prior year quarter.

Sentiment

Score: 3

Explanation: While there are some positive operational highlights like service revenue growth and improved gross margins, the significant decline in net sales and shift to substantial net losses indicate a challenging financial period. The external factors cited (economic uncertainty, tariffs) suggest broader market headwinds impacting capital expenditures, which is a concern for product-focused sales. The forward-looking statements and backlog provide some optimism, but the current financial performance is poor.

Positives

• Service and training revenue increased by $93,000 (33%) year-over-year for Q2 2025, reaching $378,000.
• Service and training revenue increased by $299,000 (46%) year-over-year for the six months ended June 30, 2025, reaching $955,000.
• Gross profit margin improved to 66% in Q2 2025 from 62% in Q2 2024, attributed to a favorable product mix including higher sales of BIT solution and service offerings.
• SteraMist solution sales were up 40% year-over-year for the six months ended June 30, 2025.
• Reduced selling, research, and administrative expenses year-to-date, demonstrating disciplined cost management.
• Continued penetration into global markets, with nearly 20% of Q2 revenue generated internationally.
• Sales order backlog as of June 30, 2025, totaled approximately $1.4 million.
• Combined total of recognized revenue, deferred revenue, and sales order backlog was approximately $4.6 million as of August 7, 2025, with active projects on schedule for delivery in 2025.
• Open opportunities for Custom Engineered System (CES), Hybrid Solutions, and SteraMist (SIS) total approximately $15 million, of which $7 million are designated as high priority.
• Received the prestigious 2025 Disinfection and Decontamination Products Company of the Year award by MedTech Outlook on June 12, 2025.
• Announced the advancement of the new product line, the SteraMist Integration System with the Standalone (SIS-SA), with the first system installed with a leading contract development and manufacturing organization on June 16, 2025.
• Working capital was $2.8 million as of June 30, 2025.
• Cash used in operations improved by over $1 million compared to the prior year quarter, primarily due to management action on working capital with a focus on accounts receivable and inventory.

Negatives

• Net sales decreased significantly to $1,031,000 in Q2 2025 from $3,013,000 in Q2 2024, a 65.8% decline.
• Net sales decreased to $2,608,000 in the first half of 2025 from $4,127,000 in the first half of 2024, a 36.8% decline.
• Shifted from an operating income of $122,000 in Q2 2024 to an operating loss of $(1,133,000) in Q2 2025.
• Operating loss for the six months ended June 30, 2025, increased to $(1,887,000) from $(1,105,000) in the same period of 2024.
• Shifted from a net income of $30,000 in Q2 2024 to a net loss of $(1,238,000) in Q2 2025.
• Net loss for the six months ended June 30, 2025, increased to $(1,493,000) from $(1,280,000) in the same period of 2024.
• The primary driver for the sales decline was customers deferring capital expenditure projects due to the uncertain economic environment and the impact of announced and implemented tariffs on their supply chains.

Risks

• Customers deferring capital expenditure projects due to uncertain economic environment.
• Impact of announced and implemented tariffs on customer supply chains and long-term planning.
• Reliance on a single or a few products for a majority of revenues.
• General business and economic conditions.
• Ability to acquire new customers and expand sales.
• Ability to maintain and manage growth and generate sales.
• Other risks as described in SEC filings, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company plans to expand its team before year-end, adding talent in the C-suite, sales, customer support, and iHP service technicians. It is executing a focused strategy to expand recurring service contracts, drive year-on-year recurring revenue growth by increasing SteraMist solution sales, continue international presence growth, pursue additional government and institutional partnerships, strengthen balance sheet flexibility, and strengthen the corporate team to support growth. The company is negotiating approximately $2 million in new custom and integrated contracts, with bids expected to close prior to year-end. Active projects are on schedule for delivery in 2025.

Management Comments

• "While Q2 reflected a softer product sales cycle, we remain confident in our growth strategy and optimistic about our future opportunities."
• "As part of executing on this strategy, we plan to expand our team before year-end, adding talent in the C-suite, sales, customer support and IHP service technicians."
• "We are particularly encouraged by the sustained growth in our service and training division, the resilience of our margins, and the progress in broadening our customer base."
• "Our technology continues to be recognized for its effectiveness and environmental sustainability, and we remain focused on leveraging this strength to capture opportunities in both domestic and international markets."
• "I encourage investors to read our MD&A in our recent second quarter Q filings."

Industry Context

The disinfection and decontamination industry, while critical, appears to be facing headwinds from broader economic uncertainty and supply chain issues, leading customers to defer capital expenditure projects. TOMI's focus on recurring service revenue and international expansion is a strategic response to these challenges, aiming to stabilize income streams amidst fluctuating product sales. The company's recognition by MedTech Outlook suggests its technology remains highly regarded within the sector despite current financial performance.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark TOMI's performance against industry standards.
• The reported decline in product sales due to customer deferrals of capital expenditure projects, influenced by economic uncertainty and tariffs, suggests a broader industry trend of cautious spending on large equipment.
• The growth in service-based revenue and SteraMist solution sales indicates a potential shift in market demand towards consumables and ongoing services rather than large upfront capital investments in equipment, which could be a positive differentiator if sustained.

Management Changes

Stakeholder Impact

• Shareholders: Significant net loss and revenue decline could negatively impact share price and investor confidence. Potential for future growth through recurring revenue and new contracts offers a long-term perspective.
• Employees: Plans to expand the team in C-suite, sales, customer support, and iHP service technicians indicate potential job opportunities and stability for existing staff.
• Customers: Deferral of capital expenditure projects indicates caution, but continued growth in service and solution sales suggests ongoing engagement and reliance on TOMI's technology for operational needs.
• Creditors: Successful convertible note financing and improved cash used in operations suggest efforts to manage liquidity, but ongoing losses could be a concern.

Next Steps

• Expand team before year-end, adding talent in C-suite, sales, customer support, and iHP service technicians.
• Expand recurring service contracts with key customers.
• Explore new product lines and/or service offerings.
• Drive year-on-year recurring revenue growth by increasing SteraMist solution sales.
• Continue to grow international presence utilizing targeted marketing campaigns and referral business.
• Pursue additional government and institutional partnerships.
• Strengthen balance sheet flexibility through disciplined financial management.
• Strengthen corporate team to support growth.
• Negotiate approximately $2 million in new custom and integrated contracts, with bids expected to close prior to year-end.
• Active projects are on schedule for delivery in 2025.
• Hold a conference call to discuss Q2 2025 results on August 14, 2025.

Key Dates

Recommendation

While TOMI Environmental Solutions reported a substantial decline in product sales and a net loss for Q2 2025, driven by external economic factors and customer capital expenditure deferrals, there are underlying positive trends. The significant growth in service and training revenue (33% in Q2, 46% in H1) and SteraMist solution sales (up 40% in H1) indicates a resilient and growing recurring revenue stream. Gross margins also improved. The company has a substantial pipeline of open opportunities ($15 million, with $7 million high priority) and a healthy backlog, suggesting potential for future revenue. The appointment of a new CFO and a clear strategy to expand recurring contracts and strengthen the team are positive steps. Given the mixed signals – poor current product sales but strong service growth and future pipeline – a 'hold' recommendation is appropriate. Investors should monitor the conversion of the sales pipeline, the effectiveness of the new CFO in capital strategy, and the company's ability to mitigate the impact of broader economic headwinds on its product sales.

Keywords

Disinfection, Decontamination, SteraMist, Binary Ionization Technology, iHP, Infection Prevention, Environmental Solutions, Healthcare, Life Sciences, Food Safety, Commercial Markets, Biodefense, TOMZ, NASDAQ